Sierra Oncology is a late stage drug biopharmaceutical company on a quest to deliver targeted therapies that treat cancer. Co.'s main focus is the development of momelotinib, an investigational agent for the treatment of myelofibrosis. Momelotinib is an orally-bioavailable Janus kinase 1, Janus kinase 2 and Activin A receptor type 1 inhibitor with a mechanism of action, enabling it to potentially address all three hallmarks of disease in myelofibrosis: anemia of inflammation, constitutional symptoms and enlarged spleen. Co.'s portfolio also includes SRA737, a selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1, an emerging target for the treatment of cancer. The SRRA stock yearly return is shown above.
The yearly return on the SRRA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SRRA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|